Back to Search
Start Over
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
- Source :
- Journal of diabetes and its complications, vol 36, iss 2
- Publication Year :
- 2022
- Publisher :
- eScholarship, University of California, 2022.
-
Abstract
- Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM.
- Subjects :
- Kidney Disease
Endocrinology, Diabetes and Metabolism
Clinical Trials and Supportive Activities
Chronic Liver Disease and Cirrhosis
Clinical Sciences
Heart failure
Clinical practice
Cardiovascular
Cardiovascular System
Hepatitis
7.3 Management and decision making
Endocrinology & Metabolism
Endocrinology
7.1 Individual care needs
Clinical Research
Chronic kidney disease
Internal Medicine
Diabetes Mellitus
Humans
Hypoglycemic Agents
Consensus recommendations
Renal Insufficiency
Renal Insufficiency, Chronic
Chronic
Metabolic and endocrine
Liver Disease
Prevention
Diabetes
Type 2 diabetes
Heart Disease
Good Health and Well Being
Diabetes Mellitus, Type 2
Cardiovascular Diseases
Atherosclerotic cardiovascular disease
Management of diseases and conditions
Digestive Diseases
Type 2
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- Journal of diabetes and its complications, vol 36, iss 2
- Accession number :
- edsair.doi.dedup.....044f7715c68543ae6394b075ee1271a8